- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Decline of Clinical Trials in Central and Eastern Europe
Currently, 66% of clinical trials are conducted in North America, Western Europe and Australia.
Currently, 66% of clinical trials are conducted in North America, Western Europe and Australia. The U.S. hosts 49% of clinical trial sites and generates approximately 40% of clinical data. Other regions have arisen in recent years. The main reasons behind this globalization trend are the availability of highly skilled professionals in new research markets, lower costs, faster patient recruitment that allows for earlier drug application approvals and concentrations of huge populations for future drug sales.
Central and Eastern Europe participates in about 13% of clinical trials conducted in Europe and in about 5% of those conducted globally.
However, this number was as high as 7.5% in 2006. In relative terms, the decline here goes as far as 28% over the last six years. It has been observed in all countries of this region, especially Poland, Croatia and the Baltic states.
In this Applied Clinical Trials article, Thomas Novak, Maxim Belotserkovsky, and Ginny Payeur look at whether this surprising finding represents a fluctuation or a new trend.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
